Trend
DailyDowntrend (confirmed)
4 hourLeaning Bullish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bullish
Daily trend turns up above $0.91
Key levels
Resistance$0.56
Resistance$0.43
Support$0.30
Latest news & SEC filings
ProductLucid Diagnostics Publishes 12,000-Patient EsoGuard Study
ProductPAVmed's Lucid Diagnostics publishes EsoGuard esophageal precancer testing findings
All LUCD news →This company develops and sells tests aimed at catching esophageal cancer before it develops in people with long-term acid reflux. Its main offering combines a laboratory DNA test with a swallowable balloon capsule device that gathers cells from the esophagus during a brief office visit. Testing is handled through the company's own lab and made available via its testing sites, doctors' offices, mobile units, employers, and a telemedicine service, mainly within the United States.
Based on the company's 10-K filed Mar 25, 2026.
Nasdaq · Healthcare
SEPT Low Target
$2.00
SEPT Mid Target
$2.25
SEPT High Target
$2.50
Analyst Consensus
$2.25
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for LUCD.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$2.25
13
Moat Score
NONE
4/9
Piotroski Score
-12.3
Altman Z-Score
Insider Signal
NEUTRAL
1 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Matheis Dennis | director | Buy | 245,000 | $245K | May 20, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
8.3%
3yr Revenue CAGR
132.0%
EPS Growth YoY
N/A
FCF Growth YoY
-5.0%
Revenue Trend
STRONG
SEPT Investing tracks real-time dark pool institutional trades for LUCD, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 24:11:58 | $0.39 | 4,208 | $$2K | SELL |
| 23:40:55 | $0.39 | 1,000 | $$390 | BUY |
| 22:58:03 | $0.38 | 4,208 | $$2K | SELL |
| 21:26:53 | $0.38 | 270,984 | $$103K | SELL |
| 20:59:37 | $0.39 | 1,342 | $$522 | SELL |
5 dark pool trades shown · $$107K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Lucid Diagnostics Inc. (LUCD) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Lucid Diagnostics Inc. (LUCD) is at $0.42, up 9.15% (+$0.03) at the Nov 12, 2026 close.
Latest LUCD news — Nov 3, 2026: Lucid Diagnostics Publishes 12,000-Patient EsoGuard Study · Nov 3, 2026: PAVmed's Lucid Diagnostics publishes EsoGuard esophageal precancer testing findings
The average analyst price target for LUCD is $2.25, ranging from $2 to $3, based on 2 analysts.
Analyst ratings for LUCD: 0 Buy, 10 Hold, 0 Sell — consensus Hold.
LUCD last reported on Aug 13, 2026: EPS -$0.06 vs -$0.07 expected — a beat of 14.3%.
LUCD does not currently pay a dividend.
Support: $0.30. Resistance: $0.43, $0.56, $0.63.
Insider activity: NEUTRAL, 1 buys and 0 sells in the last 90 days.
Nov 3, 2026: Lucid Diagnostics Publishes 12,000-Patient EsoGuard Study · Nov 3, 2026: PAVmed's Lucid Diagnostics publishes EsoGuard esophageal precancer testing findings